Q32 Bio shares drew renewed attention on Wednesday after the FDA granted Fast Track designation to its experimental alopecia areata treatment, bempikibart. The designation could accelerate development and review of the Phase 2-stage therapy.
CFO Akash Palkhiwala acknowledged the uncertainty around the impact of the global trade landscape on demand across the company’s businesses, according to Koyfin’s transcript.
US equities have now erased almost 90% of their losses seen in the aftermath of 'Liberation Day'. The mood music on trade has improved slightly, and a US-Ukraine minerals deal helps, too.
Prominent short seller Jim Chanos has challenged the U.S. government's manufacturing aspirations, highlighting the economic realities keeping iPhone production overseas.
A U.S. District Judge found Apple in contempt of court for evading a 2021 injunction related to its App Store payment practices, accusing the company of lying under oath and withholding key documents, while also referring the matter for potential criminal contempt charges.
With no data in, the GDPNow model starts off the second quarter with a nowcast of 2.4 percent. A deeper dive into the model data has Real Final Sales at 2.6 percent to start the quarter.
Recent data challenges the traditional "Sell in May and go away" market adage, with evidence suggesting investors might be better off delaying portfolio adjustments.
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance.
Nearly two years after its launch, World (CRYPTO: WLD), co-founded by OpenAI CEO Sam Altman, debuted in the U.S. on Thursday. The decentralized identity verification project also unveiled a new smartphone-like device for identity verification and a debit card to make WLD payments.
Silver (XAG/USD) drifts lower for the third straight day – also marking the fourth day of a negative move in the previous five – and drops to over a two-week low during the Asian session on Thursday.
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.
Microsoft plans to leverage its cloud services and customer-centric solutions to not only survive a recession but also grow by helping businesses manage economic challenges.
